Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613652 | 0.85 | PARP1 (0.40) | PARP1ADORA3PDE10ATYMPPLAT | |
| SCHEMBL1279218 | 0.84 | KCNQ3 (0.35) | PARP1ADORA3KDM5BKDM4EALDH1A1 | |
| SCHEMBL1615005 | 0.81 | ALDH1A1 (0.38) | PARP1ADORA3PDE10ATYMPPLAT | |
| SCHEMBL1613643 | 0.80 | KDM4E (0.41) | PARP1ADORA3PLATKDM4EALDH1A1 | |
| SCHEMBL1613668 | 0.80 | ADORA3 (0.39) | PARP1ADORA3KDM4EALDH1A1HPGD | |
| SCHEMBL1279326 | 0.80 | MEN1 (0.38) | PARP1ADORA3PDE10ATYMPKDM4E | |
| SCHEMBL1614734 | 0.77 | MAPK14 (0.40) | PARP1ADORA3TYMPKDM4EALDH1A1 | |
| SCHEMBL1614981 | 0.77 | KCNQ3 (0.37) | PARP1ADORA3TYMPPLATKDM4E | |
| SCHEMBL1614313 | 0.76 | PIM1 (0.44) | ADORA3PDE10AKDM4EALDH1A1HPGD | |
| SCHEMBL1613692 | 0.75 | PARP1 (0.36) | PARP1ADORA3PDE10APLATKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796285-B2 | Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof | HEBEI MEDICAL UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | PEKING UNIVERSITY (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | KCNJ2, KCNQ5, KCNJ11 | PARP1 640/4885ADORA3 164/4885KDM5B 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.